Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the heartmate II left ventricular assist device

Stuart D. Russell, Joseph G. Rogers, Carmelo A. Milano, David B. Dyke, Francis D. Pagani, Juan M. Aranda, Charles T. Klodell, Andrew J. Boyle, Ranjit John, Leway Chen, H. Todd Massey, David J. Farrar, John V. Conte

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

BACKGROUND-The effects of continuous blood flow and reduced pulsatility on major organ function have not been studied in detail. METHODS AND RESULTS-We evaluated renal (creatinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) advanced heart failure patients who had been supported with the HeartMate II continuous-flow left ventricular assist device for bridge to transplantation. To determine whether patients with impaired renal and hepatic function improve over time with continuous-flow left ventricular assist device support or whether there are any detrimental effects in patients with normal organ function, we divided patients into those with above-normal and normal laboratory values before implantation and measured blood chemistry over time during left ventricular assist device support. There were significant improvements over 6 months in all parameters in the above-normal groups, with values in the normal groups remaining in the normal range over time. Mean blood urea nitrogen and serum creatinine in the above-normal groups decreased significantly from 37±14 to 23±10 mg/dL (P<0.0001) and from 1.8±0.4 to 1.4±0.8 mg/dL (P<0.01), respectively. There were decreases in aspartate transaminase and alanine transaminase in the above-normal groups from 121±206 and 171±348 to 36±19 and 31±22 IU (P<0.001), respectively. Total bilirubin for the above-normal group was 2.1±0.9 mg/dL at baseline; after an acute increase at week 1, it decreased to 0.9±0.5 mg/dL by 6 months (P<0.0001). Both renal and liver values from patients in the normal groups remained normal during support with the left ventricular assist device. CONCLUSIONS-The HeartMate II continuous-flow left ventricular assist device improves renal and hepatic function in advanced heart failure patients who are being bridged to transplantation, without evidence of detrimental effects from reduced pulsatility over a 6-month time period.

Original languageEnglish (US)
Pages (from-to)2352-2357
Number of pages6
JournalCirculation
Volume120
Issue number23
DOIs
StatePublished - Dec 1 2009

Fingerprint

Heart-Assist Devices
Heart Failure
Kidney
Liver
Reference Values
Blood Urea Nitrogen
Aspartate Aminotransferases
Alanine Transaminase
Bilirubin
Creatinine
Transplantation
Serum

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Russell, Stuart D. ; Rogers, Joseph G. ; Milano, Carmelo A. ; Dyke, David B. ; Pagani, Francis D. ; Aranda, Juan M. ; Klodell, Charles T. ; Boyle, Andrew J. ; John, Ranjit ; Chen, Leway ; Massey, H. Todd ; Farrar, David J. ; Conte, John V. / Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the heartmate II left ventricular assist device. In: Circulation. 2009 ; Vol. 120, No. 23. pp. 2352-2357.
@article{7f253369cd0f428fa083c323b5682acb,
title = "Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the heartmate II left ventricular assist device",
abstract = "BACKGROUND-The effects of continuous blood flow and reduced pulsatility on major organ function have not been studied in detail. METHODS AND RESULTS-We evaluated renal (creatinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) advanced heart failure patients who had been supported with the HeartMate II continuous-flow left ventricular assist device for bridge to transplantation. To determine whether patients with impaired renal and hepatic function improve over time with continuous-flow left ventricular assist device support or whether there are any detrimental effects in patients with normal organ function, we divided patients into those with above-normal and normal laboratory values before implantation and measured blood chemistry over time during left ventricular assist device support. There were significant improvements over 6 months in all parameters in the above-normal groups, with values in the normal groups remaining in the normal range over time. Mean blood urea nitrogen and serum creatinine in the above-normal groups decreased significantly from 37±14 to 23±10 mg/dL (P<0.0001) and from 1.8±0.4 to 1.4±0.8 mg/dL (P<0.01), respectively. There were decreases in aspartate transaminase and alanine transaminase in the above-normal groups from 121±206 and 171±348 to 36±19 and 31±22 IU (P<0.001), respectively. Total bilirubin for the above-normal group was 2.1±0.9 mg/dL at baseline; after an acute increase at week 1, it decreased to 0.9±0.5 mg/dL by 6 months (P<0.0001). Both renal and liver values from patients in the normal groups remained normal during support with the left ventricular assist device. CONCLUSIONS-The HeartMate II continuous-flow left ventricular assist device improves renal and hepatic function in advanced heart failure patients who are being bridged to transplantation, without evidence of detrimental effects from reduced pulsatility over a 6-month time period.",
author = "Russell, {Stuart D.} and Rogers, {Joseph G.} and Milano, {Carmelo A.} and Dyke, {David B.} and Pagani, {Francis D.} and Aranda, {Juan M.} and Klodell, {Charles T.} and Boyle, {Andrew J.} and Ranjit John and Leway Chen and Massey, {H. Todd} and Farrar, {David J.} and Conte, {John V.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1161/CIRCULATIONAHA.108.814863",
language = "English (US)",
volume = "120",
pages = "2352--2357",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

Russell, SD, Rogers, JG, Milano, CA, Dyke, DB, Pagani, FD, Aranda, JM, Klodell, CT, Boyle, AJ, John, R, Chen, L, Massey, HT, Farrar, DJ & Conte, JV 2009, 'Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the heartmate II left ventricular assist device', Circulation, vol. 120, no. 23, pp. 2352-2357. https://doi.org/10.1161/CIRCULATIONAHA.108.814863

Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the heartmate II left ventricular assist device. / Russell, Stuart D.; Rogers, Joseph G.; Milano, Carmelo A.; Dyke, David B.; Pagani, Francis D.; Aranda, Juan M.; Klodell, Charles T.; Boyle, Andrew J.; John, Ranjit; Chen, Leway; Massey, H. Todd; Farrar, David J.; Conte, John V.

In: Circulation, Vol. 120, No. 23, 01.12.2009, p. 2352-2357.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the heartmate II left ventricular assist device

AU - Russell, Stuart D.

AU - Rogers, Joseph G.

AU - Milano, Carmelo A.

AU - Dyke, David B.

AU - Pagani, Francis D.

AU - Aranda, Juan M.

AU - Klodell, Charles T.

AU - Boyle, Andrew J.

AU - John, Ranjit

AU - Chen, Leway

AU - Massey, H. Todd

AU - Farrar, David J.

AU - Conte, John V.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - BACKGROUND-The effects of continuous blood flow and reduced pulsatility on major organ function have not been studied in detail. METHODS AND RESULTS-We evaluated renal (creatinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) advanced heart failure patients who had been supported with the HeartMate II continuous-flow left ventricular assist device for bridge to transplantation. To determine whether patients with impaired renal and hepatic function improve over time with continuous-flow left ventricular assist device support or whether there are any detrimental effects in patients with normal organ function, we divided patients into those with above-normal and normal laboratory values before implantation and measured blood chemistry over time during left ventricular assist device support. There were significant improvements over 6 months in all parameters in the above-normal groups, with values in the normal groups remaining in the normal range over time. Mean blood urea nitrogen and serum creatinine in the above-normal groups decreased significantly from 37±14 to 23±10 mg/dL (P<0.0001) and from 1.8±0.4 to 1.4±0.8 mg/dL (P<0.01), respectively. There were decreases in aspartate transaminase and alanine transaminase in the above-normal groups from 121±206 and 171±348 to 36±19 and 31±22 IU (P<0.001), respectively. Total bilirubin for the above-normal group was 2.1±0.9 mg/dL at baseline; after an acute increase at week 1, it decreased to 0.9±0.5 mg/dL by 6 months (P<0.0001). Both renal and liver values from patients in the normal groups remained normal during support with the left ventricular assist device. CONCLUSIONS-The HeartMate II continuous-flow left ventricular assist device improves renal and hepatic function in advanced heart failure patients who are being bridged to transplantation, without evidence of detrimental effects from reduced pulsatility over a 6-month time period.

AB - BACKGROUND-The effects of continuous blood flow and reduced pulsatility on major organ function have not been studied in detail. METHODS AND RESULTS-We evaluated renal (creatinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) advanced heart failure patients who had been supported with the HeartMate II continuous-flow left ventricular assist device for bridge to transplantation. To determine whether patients with impaired renal and hepatic function improve over time with continuous-flow left ventricular assist device support or whether there are any detrimental effects in patients with normal organ function, we divided patients into those with above-normal and normal laboratory values before implantation and measured blood chemistry over time during left ventricular assist device support. There were significant improvements over 6 months in all parameters in the above-normal groups, with values in the normal groups remaining in the normal range over time. Mean blood urea nitrogen and serum creatinine in the above-normal groups decreased significantly from 37±14 to 23±10 mg/dL (P<0.0001) and from 1.8±0.4 to 1.4±0.8 mg/dL (P<0.01), respectively. There were decreases in aspartate transaminase and alanine transaminase in the above-normal groups from 121±206 and 171±348 to 36±19 and 31±22 IU (P<0.001), respectively. Total bilirubin for the above-normal group was 2.1±0.9 mg/dL at baseline; after an acute increase at week 1, it decreased to 0.9±0.5 mg/dL by 6 months (P<0.0001). Both renal and liver values from patients in the normal groups remained normal during support with the left ventricular assist device. CONCLUSIONS-The HeartMate II continuous-flow left ventricular assist device improves renal and hepatic function in advanced heart failure patients who are being bridged to transplantation, without evidence of detrimental effects from reduced pulsatility over a 6-month time period.

UR - http://www.scopus.com/inward/record.url?scp=73449133718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449133718&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.108.814863

DO - 10.1161/CIRCULATIONAHA.108.814863

M3 - Article

C2 - 19933938

AN - SCOPUS:73449133718

VL - 120

SP - 2352

EP - 2357

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 23

ER -